Polycystic ovary syndrome resembling histopathological alterations in ovaries from prenatal androgenized female rats

Journal of Ovarian Research

Xuefeng Xia¹  Jiachun Lu¹  Jianqiao Liu¹  Wenjing Yang²  Bolan Yu¹  Fang Wang¹ 

[1] Institute of Gynecology and Obstetrics, the Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, China;Wuhan 6th People’s Hospital, Wuhan, 430015, China

关键词: Rat model;    Ovarian;    Polycystic ovary syndrome (PCOS);    Prenatal androgenization;   

Others  :  815107
DOI  :  10.1186/1757-2215-5-15

 received in 2012-04-07, accepted in 2012-05-18,  发布年份 2012

【 摘 要 】

Background

The polycystic ovary syndrome (PCOS) affects approximately 6-10% of women of reproductive age and is characterized by chronic anovulation and hyperandrogenism. However, a comprehensive understanding of the mechanisms that dictate androgen overproduction is lacking, which may account for inconsistencies between measures of androgen excess and clinical presentation in individual cases.

Methods

A rat model of PCOS was established by injecting dehydroepiandrosterone sulfoconjugate (DHEAS) into pregnant females. Rats were administered with DHEAS (60 mg/kg/d) subcutaneously (s.c.) for all 20 days of pregnancy (Group A), or for the first 10 days (Group B), or from day 11 to day 20 (Group C). Controls were administered with injection oil (0.2 ml/day) s.c. throughout pregnancy (Group D). The litter rate, abortion rate, and offspring survival rate in each group were recorded. Serum androgen and estrogen were measured and the morphological features of the ovaries were examined by light and electron microscopy in the offspring of each group.

Results

We found that rats injected with DHEAS throughout pregnancy (group A) lost fertility. Rats injected with DHEAS during early pregnancy (group B) exhibited more serious aberrations in fertility than both Group C, in which rats were injected with DHEAS during late pregnancy (P < 0.05), and Group D (controls). There was a statistical difference of ovarian weight among female offspring in Group B, C and D (P < 0.01). By light and electron microscopy, a significant morphological difference among the female offspring in the three groups was observed.

Conclusions

Our results indicate that androgen excess during pregnancy can decrease rat fertility. Excess androgen at the early stage of pregnancy causes high reproductive toxicity, leading to abnormality of ovarian morphology and functions in female offspring.

【 授权许可】

   
2012 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Norman RJ, Dewailly D, Legro RS, Hickey TE: Polycystic ovary syndrome. Lancet 2007, 370:685-697.
• [2]Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO: The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004, 89:2745-2749.
• [3]Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R: Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998, 83:3078-3082.
• [4]Crosignani PG, Nicolosi AE: Polycystic ovarian disease: heritability and heterogeneity. Hum Reprod Update 2001, 7:3-7.
• [5]de Zegher F, Ibanez L: Early Origins of polycystic ovary syndrome: hypotheses may change without notice. J Clin Endocrinol Metab 2009, 94:3682-3685.
• [6]Dumesic DA, Abbott DH, Padmanabhan V: Polycystic ovary syndrome and its developmental origins. Rev Endocr Metab Disord 2007, 8:127-141.
• [7]Abbott DH, Dumesic DA, Eisner JR, Colman RJ, Kemnitz JW: Insights into the development of polycystic ovary syndrome (PCOS) from studies of prenatally androgenized female rhesus monkeys. Trends Endocrinol Metab 1998, 9:62-67.
• [8]Zhou R, Bird IM, Dumesic DA, Abbott DH: Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90:6630-6637.
• [9]Wild RA, Umstot ES, Andersen RN, Ranney GB, Givens JR: Androgen parameters and their correlation with body weight in one hundred thirty-eight women thought to have hyperandrogenism. Am J Obstet Gynecol 1983, 146:602-606.
• [10]Ibanez L, Dimartino-Nardi J, Potau N, Saenger P: Premature adrenarche–normal variant or forerunner of adult disease? Endocr Rev 2000, 21:671-696.
• [11]McCartney CR, Blank SK, Prendergast KA, Chhabra S, Eagleson CA, Helm KD, Yoo R, Chang RJ, Foster CM, Caprio S, Marshall JC: Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. J Clin Endocrinol Metab 2007, 92:430-436.
• [12]Abbott DH, Barnett DK, Levine JE, Padmanabhan V, Dumesic DA, Jacoris S, Tarantal AF: Endocrine antecedents of polycystic ovary syndrome in fetal and infant prenatally androgenized female rhesus monkeys. Biol Reprod 2008, 79:154-163.
• [13]Abbott DH, Tarantal AF, Dumesic DA: Fetal, infant, adolescent and adult phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus monkeys. Am J Primatol 2009, 71:776-784.
• [14]Bruns CM, Baum ST, Colman RJ, Dumesic DA, Eisner JR, Jensen MD, Whigham LD, Abbott DH: Prenatal androgen excess negatively impacts body fat distribution in a nonhuman primate model of polycystic ovary syndrome. Int J Obes (Lond) 2007, 31:1579-1585.
• [15]Dumesic DA, Patankar MS, Barnett DK, Lesnick TG, Hutcherson BA, Abbott DH: Early prenatal androgenization results in diminished ovarian reserve in adult female rhesus monkeys. Hum Reprod 2009, 24:3188-3195.
• [16]Manikkam M, Steckler TL, Welch KB, Inskeep EK, Padmanabhan V: Fetal programming: prenatal testosterone treatment leads to follicular persistence/luteal defects; partial restoration of ovarian function by cyclic progesterone treatment. Endocrinology 2006, 147:1997-2007.
• [17]Sarma HN, Manikkam M, Herkimer C, Dell'Orco J, Welch KB, Foster DL, Padmanabhan V: Fetal programming: excess prenatal testosterone reduces postnatal luteinizing hormone, but not follicle-stimulating hormone responsiveness, to estradiol negative feedback in the female. Endocrinology 2005, 146:4281-4291.
• [18]Veiga-Lopez A, Steckler TL, Abbott DH, Welch KB, MohanKumar PS, Phillips DJ, Refsal K, Padmanabhan V: Developmental programming: impact of excess prenatal testosterone on intrauterine fetal endocrine milieu and growth in sheep. Biol Reprod 2011, 84:87-96.
• [19]Demissie M, Lazic M, Foecking EM, Aird F, Dunaif A, Levine JE: Transient prenatal androgen exposure produces metabolic syndrome in adult female rats. Am J Physiol Endocrinol Metab 2008, 295:E262-E268.
• [20]Wu XY, Li ZL, Wu CY, Liu YM, Lin H, Wang SH, Xiao WF: Endocrine traits of polycystic ovary syndrome in prenatally androgenized female Sprague–Dawley rats. Endocr J 2010, 57:201-209.
• [21]Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, Marshall JC: Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 2000, 85:4047-4052.
• [22]Gilling-Smith C, Willis DS, Beard RW, Franks S: Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 1994, 79:1158-1165.
• [23]Abbott DH, Dumesic DA, Franks S: Developmental origin of polycystic ovary syndrome - a hypothesis. J Endocrinol 2002, 174:1-5.
• [24]Franks S: Do animal models of polycystic ovary syndrome help to understand its pathogenesis and management? Yes, but their limitations should be recognized. Endocrinology 2009, 150:3983-3985.
• [25]Anderson E, Lee GY, O'Brien K: Polycystic ovarian condition in the dehydroepiandrosterone -treated rat model: hyperandrogenism and the resumption of meiosis are major initial events associated with cystogenesis of antral follicles. Anat Rec 1997, 249:44-53.
• [26]Dumesic DA, Schramm RD, Bird IM, Peterson E, Paprocki AM, Zhou R, Abbott DH: Reduced intrafollicular androstenedione and estradiol levels in early-treated prenatally androgenized female rhesus monkeys receiving follicle-stimulating hormone therapy for in vitro fertilization. Biol Reprod 2003, 69:1213-1219.